Chinook Therapeutics, Inc. KDNY
We take great care to ensure that the data presented and summarized in this overview for CHINOOK THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KDNY
View all-
Tekla Capital Management LLC151KShares$00.23% of portfolio
-
Health Cor Management, L.P. New York, NY60KShares$01.49% of portfolio
-
Pictet Asset Management Sa Geneva 73, V822.8KShares$00.0% of portfolio
-
Farther Finance Advisors, LLC San Francisco, CA100Shares$00.0% of portfolio
-
Parallel Advisors, LLC5Shares$00.0% of portfolio
Latest Institutional Activity in KDNY
Top Purchases
Top Sells
About KDNY
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Insider Transactions at KDNY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2023
|
Andrew James King Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,157
-100.0%
|
-
|
|
Aug 11
2023
|
Mahesh Krishnan Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,275
-100.0%
|
-
|
|
Aug 11
2023
|
Dolca Thomas Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,300
-100.0%
|
-
|
|
Aug 11
2023
|
Eric Bjerkholt Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
39,371
-100.0%
|
-
|
|
Aug 11
2023
|
Davis Jerel Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,035,207
-100.0%
|
-
|
|
Aug 11
2023
|
Davis Jerel Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
447,013
-100.0%
|
-
|
|
Aug 11
2023
|
Eric Dobmeier President, CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
301,138
-100.0%
|
-
|
|
Aug 11
2023
|
Tom Frohlich Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,777
-100.0%
|
-
|
|
Aug 11
2023
|
William Mariner Greenman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,643
-100.0%
|
-
|
|
Aug 11
2023
|
Michelle Renee Griffin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,300
-100.0%
|
-
|
|
Aug 11
2023
|
Srinivas Akkaraju Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,161,888
-100.0%
|
-
|
|
Aug 11
2023
|
Srinivas Akkaraju Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,300
-100.0%
|
-
|
|
Aug 01
2023
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,168
-5.75%
|
$45,552
$39.03 P/Share
|
|
Jul 29
2023
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+14.09%
|
-
|
|
May 30
2023
|
William Mariner Greenman Director |
SELL
Open market or private sale
|
Direct |
1,155
-4.66%
|
$26,565
$23.3 P/Share
|
|
May 26
2023
|
Ross Haghighat Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+2.58%
|
-
|
|
May 26
2023
|
Srinivas Akkaraju Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+50.0%
|
-
|
|
May 26
2023
|
William Mariner Greenman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+11.74%
|
-
|
|
May 26
2023
|
Dolca Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+19.88%
|
-
|
|
May 26
2023
|
Davis Jerel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+0.45%
|
-
|